David Zaccardelli joins Vor Biopharma (NASDAQ: VOR) board after Levin exit
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Vor Biopharma Inc. reported a board change, with Andrew Levin, M.D., Ph.D., resigning as a director effective July 6, 2026. His resignation was explicitly stated not to result from any disagreement with the company. The board expressed appreciation for his service.
On July 7, 2026, the board appointed David Zaccardelli, Pharm.D. as an independent Class II director to fill the vacancy, with a term running until the 2029 annual meeting of stockholders. He brings prior CEO and director experience at multiple public pharmaceutical companies that were later acquired.
For his board service, Dr. Zaccardelli will receive an annual cash retainer of $40,000 and an initial stock option grant covering up to 68,000 shares or options with a grant-date fair value of $700,000, plus ongoing annual option grants tied to either 34,000 shares or $350,000 in grant-date value.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Director resignation date: July 6, 2026
New director term end: 2029 annual meeting
Annual cash retainer: $40,000
+5 more
8 metrics
Director resignation date
July 6, 2026
Effective resignation of Andrew Levin, M.D., Ph.D.
New director term end
2029 annual meeting
End of term for Class II director David Zaccardelli
Annual cash retainer
$40,000
Yearly board service fee for David Zaccardelli
Initial option shares cap
68,000 shares
Maximum shares under initial stock option grant
Initial option value cap
$700,000
Aggregate grant date fair value limit for initial grant
Annual option shares cap
34,000 shares
Maximum shares under each annual option grant
Annual option value cap
$350,000
Aggregate grant date fair value limit for annual grants
New director age
61
Age of David Zaccardelli, Pharm.D.
Key Terms
Emerging growth company, Nasdaq Global Select Market, Non-Employee Directors’ Compensation Policy, indemnification agreement, +1 more
5 terms
Emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nasdaq Global Select Market market
"Common Stock, $0.0001 par value per share | | VOR | | Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Non-Employee Directors’ Compensation Policy financial
"standard non-employee director cash and equity compensation under its Non-Employee Directors’ Compensation Policy"
indemnification agreement regulatory
"Dr. Zaccardelli will also enter into the Company’s standard form of indemnification agreement."
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Class II director governance
"to serve on the Board as an independent Class II director until the Company’s 2029 annual meeting"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
FAQ
What board change did Vor Biopharma (VOR) announce in this 8-K?
Vor Biopharma announced that Andrew Levin, M.D., Ph.D., resigned from its board, effective July 6, 2026. The company stated his resignation was not due to any disagreement and simultaneously moved to fill the vacancy with a new independent director.
Who joined the Vor Biopharma (VOR) board and how long is his term?
Vor Biopharma appointed David Zaccardelli, Pharm.D., as an independent Class II director. He will serve until the company’s 2029 annual meeting of stockholders and continue until his successor is elected and qualified or he resigns or is removed earlier.
What is the director compensation for David Zaccardelli at Vor Biopharma (VOR)?
David Zaccardelli will receive a $40,000 annual cash retainer for board service. He will also receive an initial stock option grant based on up to 68,000 shares or $700,000 in fair value, plus smaller annual option grants tied to either 34,000 shares or $350,000.
Did Andrew Levin resign from Vor Biopharma (VOR) due to a disagreement?
The company stated that Andrew Levin’s decision to resign from the Vor Biopharma board was not the result of any disagreement. This clarification suggests the departure is not linked to disputes over operations, policies, or practices as described in the disclosure.
Does David Zaccardelli have prior public company leadership experience relevant to Vor Biopharma (VOR)?
Yes. David Zaccardelli previously served as President and Chief Executive Officer, and as a director, at several public pharmaceutical companies, including Verona Pharma plc, Dova Pharmaceuticals, and Cempra Pharmaceuticals, each of which was later acquired by larger pharmaceutical organizations.
What equity awards can David Zaccardelli receive as a director of Vor Biopharma (VOR)?
Upon joining the board, he receives an initial option for the lesser of 68,000 shares or options valued at $700,000. Beginning with the 2027 annual meeting, he is eligible for annual options for the lesser of 34,000 shares or $350,000 in grant-date value.